Biomea Fusion: Funding, Investors & Team (Oct 2026)
Biomea Fusion is a privately-owned precision medicine company that aims to innovate drug development in order to produce better treatments for cancer patients. The company focuses on targeting specific gene mutations that play a major role in tumor growth. Biomea Fusion is committed to advancing these potentially groundbreaking medicines quickly through development to provide impactful therapies for patients. The main program is focused on inhibiting the interaction between menin and the MLL complex in order to treat various types of tumors.
Biomea Fusion has raised $121M across 3 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Oct 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Biomea Fusion Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Biomea Fusion Funding Rounds
Biomea Fusion raised $56.0M in a Series A announced in Jan 2021.
4.4 years later, an undisclosed round of $40.0M was announced in Jun 2025.
4 months later, an undisclosed round of $25.0M was announced in Oct 2025.
Biomea Fusion Founders and Leadership Team
Contact details for the Biomea Fusion team: 2 of 2 have an email address on file.
Start 14-day free trial →Biomea Fusion Funding Compared to Other Biotechnology Startups
Biomea Fusion's latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Biomea Fusion in Biotechnology and Redwood City
Companies Similar to Biomea Fusion
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Biomea Fusion Funding FAQs
What does Biomea Fusion do?
Biomea Fusion is a privately-owned precision medicine company that aims to innovate drug development in order to produce better treatments for cancer patients. The company focuses on targeting specific gene mutations that play a major role in tumor growth. Biomea Fusion is committed to advancing these potentially groundbreaking medicines quickly through development to provide impactful therapies for patients. The main program is focused on inhibiting the interaction between menin and the MLL complex in order to treat various types of tumors.
How much funding has Biomea Fusion raised?
Biomea Fusion has raised $121M across 3 rounds on record. The most recent is an undisclosed round of $25.0M announced in Oct 2025.
When did Biomea Fusion last raise funding?
Biomea Fusion's most recent funding round on record is an undisclosed round of $25.0M, announced in Oct 2025.
Who founded Biomea Fusion?
FundedIQ lists Ramses Erdtmann (Founder), Thomas Butler (Founder) at Biomea Fusion.
Where is Biomea Fusion headquartered?
Biomea Fusion is based in Redwood City, California, United States.
How many employees does Biomea Fusion have?
Biomea Fusion is in the 51-100 employee band.
How does Biomea Fusion's funding compare to other Biotechnology startups?
Biomea Fusion's latest round of $25.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Biomea Fusion Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Biomea Fusion is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.